Mass spectrometers for biopharma characterization

01Overview and value chain#

Markers EC: US FDA 21 CFR Part 11 + ICH Q6B for biopharmaceutical characterization and impurity profiling | OECD: Bio-pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)

Mass spectrometers identify and quantify molecules by measuring their mass-to-charge ratio, and in biopharma they sit at the center of protein characterization: confirming amino-acid sequence, mapping post-translational modifications such as glycosylation and oxidation, and detecting trace-level impurities and degradation products that a chromatography detector alone cannot resolve. Three architectures dominate the category. High-resolution Orbitrap instruments trap ions in an electrostatic field and resolve mass with sub-part-per-million accuracy, the workhorse for deep proteomic characterization and intact-protein mass confirmation. Time-of-flight (TOF) systems, often combined with ion mobility, measure the time ions take to traverse a flight tube to derive mass, prized for speed and resolution in single-cell and subcellular proteomics. Triple-quadrupole instruments filter and fragment ions through three sequential quadrupoles for the most sensitive targeted quantitation, the standard for peptide-biomarker and clinical/forensic assays. Coupled to liquid or gas chromatography upstream, these platforms turn a single injection into a full identity, purity and modification profile — the backbone of ICH Q6B-compliant biopharmaceutical characterization and of the impurity data a regulatory filing requires.

The key directions of mass spectrometry for biopharma are:

1. High-resolution Orbitrap mass spectrometry (Orbitrap MS): sub-ppm mass accuracy for deep proteomic characterization, intact-protein mass confirmation and comprehensive impurity profiling.
2. Time-of-flight and ion-mobility mass spectrometry (TOF/IM-MS): high-speed, high-resolution mass measurement, increasingly paired with ion mobility for single-cell and subcellular proteomics.
3. Triple-quadrupole targeted quantitation (Triple-Quad MS): the most sensitive platform for targeted peptide-biomarker quantitation and clinical/forensic assays, run in multiple-reaction-monitoring mode.
4. LC-MS/MS and GC-MS/MS hyphenation (Chromatography-Coupled MS): upstream liquid or gas chromatography separation feeding the mass spectrometer, turning a single sample injection into a full identity and purity profile.

Sectoral value chain#

[Sample: protein/peptide/small molecule] ──> [Chromatography separation] ──> [Ionization & mass analysis] ──> [Spectral data: mass, intensity, fragmentation]
                                                                  │
                                                          (identification/quantitation)
                                                                  │
                                                                  ▼
[Characterization report / batch release] <─── [Software: spectral library match, deconvolution]

Value chain levels#

Cross-cutting technologies of the sector:

• Data-independent acquisition (DIA): systematically fragments all precursor ions in defined windows rather than selecting individual precursors, improving reproducibility for large-scale proteomic studies.
• Native mass spectrometry: preserves non-covalent protein complexes and higher-order structure during ionization, extending characterization beyond primary sequence to quaternary assembly.
• AI-assisted spectral deconvolution: machine-learning models increasingly assist peak-picking and spectral-library matching for complex, high-density proteomic datasets.

02US#

The US hosts the category’s largest instrument makers and the deepest biopharma characterization and clinical-quantitation demand, spanning discovery proteomics through GxP release testing.

deep proteomic characterization, intact-protein mass confirmation, targeted clinical/forensic quantitation#

• Thermo Fisher Scientific: the Orbitrap Astral Zoom and Orbitrap Excedion Pro extend high-resolution mass spectrometry toward higher-throughput proteome profiling and intact-protein/antibody characterization, unveiled with next-generation innovations at ASMS 2026 aimed at accelerating the path from drug discovery to new therapies.
• Waters Corporation: the Xevo MRT P10 MS delivers up to 20x improved MS/MS sensitivity and 2x faster acquisition for multiomics research, while the Xevo TQ Absolute XR extends tandem-quadrupole sensitivity to clinical IVD applications.
• SCIEX: the ZenoTOF 8600 sets a new standard in accurate mass quantitation, and the TripleTOF 6600 Q-TOF platform serves high-resolution targeted and untargeted proteomics workflows.

03CN#

No China-headquartered mass spectrometer maker cleared this screening round with confirmed, on-domain evidence; demand is driven by China’s expanding biopharma characterization and clinical-quantitation needs, currently served largely through the same global vendors’ regional distribution and applications-support networks.

import-dependent instrumentation, domestic biopharma characterization demand, distributor-served market#

• Global vendor distribution: Thermo Fisher, Waters, SCIEX, Bruker and Shimadzu each maintain China sales and applications-support organizations serving domestic biopharma and clinical-diagnostics manufacturers.
• Domestic biopharma characterization build-out: China’s growing biologics manufacturing and clinical mass-spectrometry testing base is the main demand driver, without a confirmed domestic instrument originator identified in this screen.
• Screening note: two candidate China-headquartered instrument makers were probed and neither returned confirming, on-domain evidence this round — not asserted as absent, only as unconfirmed.

04EU#

Germany’s Bruker anchors Europe’s contribution with a distinct high-sensitivity ion-mobility architecture aimed at single-cell and subcellular proteomics.

ion-mobility high-resolution proteomics, single-cell/subcellular sensitivity, functional-proteomics platforms#

• Bruker (Germany): the timsTOF Ultra 2 delivers ultimate sensitivity for single-cell and subcellular proteomics, and the newer timsOmni platform advances functional proteomics with proteoform-level analysis for disease-biology research.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack layers ionization, mass analysis and software interpretation on a common chromatography-coupled sample-introduction backbone, with the choice among Orbitrap, TOF and triple-quadrupole architectures driven by whether the application prioritizes resolution, speed or targeted sensitivity.

1. Orbitrap mass analysis:
   • Ions orbit a central spindle electrode in an electrostatic field; their oscillation frequency is measured and Fourier-transformed to derive mass with sub-ppm accuracy.
   • Delivers the resolution needed to distinguish closely spaced isotope or modification peaks in intact-protein and deep-proteomic characterization.
2. Time-of-flight with ion mobility:
   • Ions are accelerated into a flight tube; time-to-detector translates directly to mass-to-charge ratio, with an added ion-mobility drift cell separating ions by shape before mass analysis.
   • The added mobility dimension resolves isobaric species that mass alone cannot distinguish, important for single-cell and subcellular proteomic complexity.
3. Triple-quadrupole targeted quantitation:
   • A first quadrupole selects a precursor ion, a second fragments it by collision, and a third quadrupole filters for a specific fragment — multiple-reaction monitoring.
   • Delivers the sensitivity and specificity needed for trace-level peptide-biomarker quantitation in clinical and forensic assays.

07Value chains and production pipelines#

Industrial pipeline of an intact-protein/impurity characterization run (ICH Q6B / 21 CFR Part 11)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Sample digestion/prep   │ ───> │ 2. Chromatographic separation │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Mass analysis           │ <─── │ 3. Ionization               │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Spectral interpretation │ ───> │ 6. Characterization report │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Sample digestion and preparation

Proteins are enzymatically digested into peptides (for bottom-up analysis) or kept intact (for top-down/intact-mass analysis), then desalted or diluted to a chromatography-ready state.

Stage 2: Chromatographic separation

Liquid or gas chromatography separates sample components over time before they reach the ion source, reducing the complexity the mass spectrometer must resolve at any instant.

Stage 3: Ionization

An electrospray or other ionization source converts eluting molecules into gas-phase ions that can be manipulated and measured by the mass analyzer.

Stage 4: Mass analysis

Orbitrap, time-of-flight or quadrupole analyzers separate the ions by mass-to-charge ratio, with optional collision-induced fragmentation providing structural information for sequence or modification confirmation.

Stage 5: Spectral interpretation

Deconvolution software and spectral-library matching assign each detected mass to a specific protein, peptide, modification or impurity species.

Stage 6: Characterization report and release

The compiled identity, purity and modification profile is compared against ICH Q6B characterization requirements or a validated release specification, with a 21 CFR Part 11-compliant audit trail for GxP environments.